BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9598143)

  • 1. Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine).
    Ruiz van Haperen VW; Veerman G; van Moorsel CJ; Peters GJ
    Adv Exp Med Biol; 1998; 431():637-40. PubMed ID: 9598143
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
    Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
    Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
    [No Abstract]   [Full Text] [Related]  

  • 3. Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.
    Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
    Adv Exp Med Biol; 1994; 370():139-43. PubMed ID: 7660877
    [No Abstract]   [Full Text] [Related]  

  • 4. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of deoxycytidine kinase in gemcitabine cytotoxicity.
    van der Wilt CL; Kroep JR; Bergman AM; Loves WJ; Alvarez E; Talianidis I; Eriksson S; van Groeningen CJ; Pinedo HM; Peters GJ
    Adv Exp Med Biol; 2000; 486():287-90. PubMed ID: 11783501
    [No Abstract]   [Full Text] [Related]  

  • 6. Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment.
    Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Ohtsuka H; Kamiie J; Abe T; Unno M; Terasaki T
    Mol Pharm; 2015 Sep; 12(9):3282-91. PubMed ID: 26280109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.
    Di Cresce C; Figueredo R; Rytelewski M; Maleki Vareki S; Way C; Ferguson PJ; Vincent MD; Koropatnick J
    Oncotarget; 2015 Sep; 6(26):22397-409. PubMed ID: 26087398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a UCMK/dCK fusion enzyme for gemcitabine-mediated cytotoxicity.
    Johnson AJ; Brown MN; Black ME
    Biochem Biophys Res Commun; 2011 Dec; 416(1-2):199-204. PubMed ID: 22093835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar changes were induced by Cladribine and by gemcitabine, in the deoxypyrimidine salvage, during short-term treatments.
    Csapó Z; Keszler G; Sasvári-Székely M; Smid K; Noordhuis P; Peters GJ; Staub M
    Adv Exp Med Biol; 1998; 431():525-9. PubMed ID: 9598122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
    Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Egawa S; Unno M; Terasaki T
    Pharm Res; 2012 Jul; 29(7):2006-16. PubMed ID: 22419259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
    Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
    Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
    Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
    Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
    Braakhuis BJ; Ruiz van Haperen VW; Boven E; Veerman G; Peters GJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):42-6. PubMed ID: 7481844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotoxicity kinetics in murine normoblasts as an approach for the in vivo action of difluorodeoxycytidine.
    Morales-Ramírez P; Vallarino-Kelly T; Cruz-Vallejo V
    Cancer Chemother Pharmacol; 2017 May; 79(5):843-853. PubMed ID: 28324147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
    Bouffard DY; Laliberté J; Momparler RL
    Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-resistance of the gemcitabine resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
    Bergman AM; Pinedo HM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
    Adv Exp Med Biol; 1998; 431():587-90. PubMed ID: 9598133
    [No Abstract]   [Full Text] [Related]  

  • 20. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
    Kroep JR; Loves WJ; van der Wilt CL; Alvarez E; Talianidis I; Boven E; Braakhuis BJ; van Groeningen CJ; Pinedo HM; Peters GJ
    Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.